The Retinoid Isomerohydrolase pipeline drugs market research report outlays comprehensive information on the Retinoid Isomerohydrolase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Retinoid Isomerohydrolase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Ophthalmology which include the indications Leber Congenital Amaurosis (LCA), and Choroideremia. It also reviews key players involved in Retinoid Isomerohydrolase targeted therapeutics development with respective active and dormant or discontinued products.
The Retinoid Isomerohydrolase pipeline targets constitutes close to seven molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, and Phase I stages are 1, 4, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Retinoid Isomerohydrolase overview
Retinoid Isomerohydrolase is an enzyme crucial for the regeneration of 11-cis-retinal, which serves as the chromophore for rod and cone opsins in the visual system. Its main role involves catalyzing the cleavage and isomerization of all-trans-retinyl fatty acid esters, converting them into 11-cis-retinol. This 11-cis-retinol is subsequently oxidized by 11-cis retinol dehydrogenase to form 11-cis-retinal, which is essential for visual processes. Additionally, Retinoid Isomerohydrolase has the capability to facilitate the isomerization of lutein to meso-zeaxanthin, a carotenoid specific to the eye.
For a complete picture of Retinoid Isomerohydrolase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
